Drug lookup | Fillwise

CABERGOLINE

All products: Limited Use (codes 656)

Other products in the same Health Canada class (G02CB) — coverage varies; not interchangeable

Bromocriptine (Parlodel): general benefit, Not a benefit
Quinagolide (Norprolac): limited Use 405

Dostinex · DIN 02242471 · 0.5mg · tablet

Limited Use — Reason for Use code 656 requiredMarketed · checked 2026-09-19

StatusLimited Use — Reason for Use code 656 required

Write on scriptLU code 656 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 656

Reason for Use code 656 For the treatment of hyperprolactinemia. Coverage limit: LU Authorization Period: Indefinite

1 brand, same coverage

Dostinex · DIN 02242471 Manufacturer: Pharmacia & Upjohn; listing date 2008-06-27 Health Canada: Marketed since 2006-01-05 · brand DOSTINEX · ATC G02CB03 CABERGOLINE · form Tablet · route Oral · ingredients CABERGOLINE 0.5 MG · company Pfizer canada ulc · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $7.2907 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66198 · Verify on the e-Formulary ↗ (DIN 02242471)

Source record

DIN 02242471: Dostinex Raw flags: sec12=Y, sec3=Y Item: 920000380; group id 902; item number 2161; lccId 00373; manufacturer id PMJ Source form: Tab; strength: 0.5mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $23.5199; ministry $7.2907 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242471 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66198

Interchangeable products

Apo-Cabergoline · DIN 02455897 · $7.2907 Jamp Cabergoline · DIN 02549611 · $7.2907

Shortage status: not checked (no credentials)

Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

QUINAGOLIDE HCL

· 1 products · Limited Use, codes 405 · strengths: 0.15mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more

Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.

What the Health Canada label says it is for

INDICATIONS AND CLINICAL USE DOSTINEX* is indicated for: Treatment of hyperprolactinemic disorders: DOSTINEX (cabergoline) is indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Inhibition of physiological lactation: DOSTINEX (cabergoline) is indicated for the prevention of the onset of physiological lactation in the puerperium for clearly defined medical reasons. These medical reasons may include birth of a still born baby, neonatal death, conditions interfering with suckling (cleft lip or palate of the baby), severe acute or chronic mental illness or medical conditions, maternal disease which may be transmitted to the baby that require medications which are excreted in the milk. Dostinex is not indicated for the purpose of suppression of already established post partum lactation. Pediatrics (<16 years of age): Safety and effectiveness of DOSTINEX in pediatric patients have not been established. Geriatrics (>65 years of age): Very limited data concerning experience of treatment of hyperprolactinemia in the elderly are available. However, available data do not indicate a special risk f… https://pdf.hres.ca/dpd_pm/00021383.PDF PM date: not printed or not captured Source product: DOSTINEX; DIN 02242471; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.